Quarterly report 2, 2025

From development to market
While we research completely new innovations and develop new products, we maintain a clear market focus. The work to build a sustainable business model where product revenues are reinvested in in-depth research is ready for implementation. Through this work, we strengthen both our position and our offering to future partners and investors.

"The strategy work is completed, and the focus is now shifting more towards a business-driven organization and delivery of our unique and fantastic research."
Michael Edelborg Christensen
CEO, ZymIQ Technology

1 Jan – 31 June 2025

• Net sales increased by 54% to SEK 1,146 thousand (744)
• Loss after tax amounted to SEK -5,212 thousand (-5,336)
• Earnings per share amounted to SEK -0.61 (–0.69)
• Cash and cash equivalents amounted to SEK 888 thousand (4,969)

1 April – 31 June 2025

• Net sales amounted to SEK 334 thousand (328)
• Loss after tax amounted to SEK -3,149 thousand (-3,157)
• Earnings per share amounted to SEK -0.37 (–0.40)

Significant events during the reporting period

• New sales to Hungary of Clean Teeth Enzyme Tab for soldiers and Kalzyme™ K9 for military service dogs.
• Kalzyme has been launched in Denmark through VetApotek in collaboration with Agria.
• The SLU study with positive results for Kalzyme™ Dental Spray has now been published.
• Clean Teeth Enzyme Tab was pre-launched at the LIW gala with a focus on young people's health and well-being.
• Floof Company represented Kalzyme™ at PetExpo, Singapore's largest pet show, while our new distributor Vet Agritech attended with Kalzyme at the VRVC Thailand Veterinary Congress.
• Börsvärlden has published two articles about ZymIQ's journey to the stock market (two out of three).
• Two more Fjör™ products are fully formulated.

Significant events after the reporting period

• Mycolysis: preclinical studies in both skin and lung model have been completed with significant results. Data are prepared for scientific publication.
• Stapholysis: feasibility study completed, and In-Vivo studies planned to be carried out during the autumn.
• SPL: development work is underway regarding the reintroduction of Staphage Lysate (SPL) and an enzyme-based immunotherapy concept for atopic dermatitis in dogs. The projects are in the early stages and further information is currently confidential.
• A placebo-controlled pilot study has been completed by Kalzyme Dental Spray. with significant results for gingivitis. The results will be published shortly.

For more information, please contact:
Michael Edelborg Christensen, CEO
Phone +46 727 144 166
Email: michael.christensen@zymiq.com

About ZymIQ
ZymIQ Technology AB (publ) is a life science company headquartered in Lund, Sweden and the parent company of the ZymIQ Group. Subsidiaries include ZymIQ Biopharma AB, Sweden and ZymIQ Animal Health LLC, Virginia, USA. The company is also represented by offices in Singapore and Malaysia. ZymIQ develops, manufactures and sells innovative enzyme-based therapeutic and cosmetic products for the well-being of humans and animals. ZymIQ also conducts pioneering research on future alternatives to antibiotics to combat the global challenge of antibiotic resistance, www.zymiq.com

Attachments
Quarterly Report Q2 2025